Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOCIVENA in Acute Myeloid Leukemia
NCT07392814Phase 1Not yet recruiting
- Sponsor
- CHU de Nantes
- Start
- Mar 2026
- Primary completion
- Jul 2028
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tocilizumab in acute myeloid leukemia (AML), sponsored by CHU de Nantes. Primary endpoint: Dose-Limiting Toxicity at 42 days. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
tocilizumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07392814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07392814.